3030-53-3

Basic information

• Product Name: Clofenoxyde
• Synonyms: Clofenoxyde;2-chloro-1-[4-[4-(2-chloroacetyl)phenoxy]phenyl]ethanone;2-chloro-1-[4-[4-(2-chloroethanoyl)phenoxy]phenyl]ethanone
• CAS NO: 3030-53-3
• Molecular Formula: C₁₆H₁₂Cl₂O₃
• Molecular Weight: 323.174
• Mol File: 3030-53-3.mol
• Article Data: 7

Chemical Properties

• Melting Point: 102 °C
• Boiling Point: 481.2°C at 760 mmHg
• Flash Point: 192°C
• Appearance: /
• Density: 1.314g/cm³
• Vapor Pressure: 2.04E-09mmHg at 25°C
• Refractive Index: 1.585
• CAS DataBase Reference: Clofenoxyde(CAS DataBase Reference)
• NIST Chemistry Reference: Clofenoxyde(3030-53-3)
• EPA Substance Registry System: Clofenoxyde(3030-53-3)

Safety Data

• Hazardous Substances Data: 3030-53-3(Hazardous Substances Data)

Usage

General Description

Clofenoxyde, also known as Flutamide, is a nonsteroidal antiandrogen drug that is primarily used to treat prostate cancer. It works by blocking the action of androgens, which are male hormones that can promote the growth of prostate cancer cells. By inhibiting the activity of androgens, Clofenoxyde can slow down the progression of the disease and reduce the size of tumors. It is often used in combination with other medications, such as LHRH agonists, to achieve the best results in the treatment of prostate cancer. While Clofenoxyde has been shown to be effective in managing the symptoms of the disease, it can also cause side effects such as liver toxicity, gynecomastia, and gastrointestinal disturbances, so it should be used with caution and under the supervision of a healthcare professional.

InChI:InChI=1/C16H12Cl2O3/c17-9-15(19)11-1-5-13(6-2-11)21-14-7-3-12(4-8-14)16(20)10-18/h1-8H,9-10H2

Upstream product

• 593-71-5 Chloroiodomethane 
• 14387-30-5 dimethyl 4,4'-oxydibenzoate 
• 101-84-8 diphenylether 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 2215-89-6 oxybis(benzoic acid) 
• 27391-25-9 bis-(4-glycyl-phenyl)-ether ; dihydrochloride 
• 5280-88-6 bis-(4-oxiranyl-phenyl)-ether 
• 114910-47-3 2,2'-dimethyl-1,1'-(4,4'-oxy-di-phenacyl)-bis-pyridinium; dichloride 
• 120639-79-4 bis-(4-pyridinioacetyl-phenyl)-ether ; dichloride 
• 112222-71-6 1-[4-(4-chloroacetyl-phenoxy)-phenacyl]-pyridinium; chloride 
• 857617-08-4 bis-(4-piperidinoacetyl-phenyl)-ether 
• 857617-11-9 bis-(4-acetoxyacetyl-phenyl)-ether 
• 1250935-62-6 C₃₆H₄₆N₄O₉ 
• 1240427-94-4 C₃₆H₄₄N₆O₅ 
• 1240427-81-9 (2S,2'S)-1-tert-butyl '2,2-2,2'-(4,4'-oxybis(4,1-phenylene))bis(2-oxo-ethane-2,1-diyl)dipyrrolidine-1,2-dicarboxylate 

Relevant articles and documents

The impact of graphene nano-plates on the behavior of novel conducting polyazomethine nanocomposites

The aim of the current work was to synthesize a new series of polyazomethine/graphene nano-plate nanocomposites in the form of PAMs/GNPa-e. Different compositions were fabricated according to the percentage of GNP loading. The composites were f

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.